Basilea-Logo.jpg
- - - Test - - - Basilea Pharmaceutica's Phase II Studie mit BAL4079 zeigt erfolgversprechende Resultate in der Behandlung von Patienten mit chronischem Handekzem - - - Test - - -
June 18, 2003 10:16 ET | Basilea Pharmaceutica AG
Basilea Pharmaceutica Ltd. gab heute die Resultate einer Doppelblind-Dosisfindungsstudie mit dem Präparat BAL4079 bei Patienten mit refraktärem chronischem Handekzem bekannt. Es konnte eine...
Basilea-Logo.jpg
Basilea announces positive Phase II results of BAL4079 (alitretinoin) in refractory chronic hand dermatitis.
March 21, 2003 09:07 ET | Basilea Pharmaceutica AG
Basel, Switzerland - 21st  March 2003   Basilea Pharmaceutica Ltd announced today that its double-blind, placebo-controlled, randomized, dose finding study of BAL4079 in patients with...
Basilea-Logo.jpg
Basilea Announces Positive Phase II Results of BAL4079 (Alitretinoin) in Refractory Chronic Hand Dermatitis
March 21, 2003 06:00 ET | Basilea Pharmaceutica AG
Basel, Switzerland, 21 March 2003   Basilea Pharmaceutica Ltd announced today that its double-blind, placebo-controlled, randomized, dose finding study of BAL4079 in patients with chronic...
Basilea-Logo.jpg
Basilea announces positive Phase II results of BAL4079 (alitretinoin) in refractory chronic hand dermatitis.
March 21, 2003 01:36 ET | Basilea Pharmaceutica AG
Basel, Switzerland - 21st  March 2003 Basilea Pharmaceutica Ltd announced today that its double-blind, placebo-controlled, randomized, dose finding study of BAL4079 in patients with chronic...
Basilea-Logo.jpg
Basilea Pharmaceutica's Phase II Studie mit BAL4079 zeigt erfolgversprechende Resultate in der Behandlung von Patienten mit chronischem Handekzem
March 21, 2003 01:36 ET | Basilea Pharmaceutica AG
Basel, 21.März, 2003   Basilea Pharmaceutica's Phase II Studie mit BAL4079 zeigt erfolgversprechende Resultate in der Behandlung von Patienten mit chronischem Handekzem   Basilea...
Basilea-Logo.jpg
FDA Fast Track Designation for Basilea's Novel Broad Spectrum Antibiotic
March 10, 2003 06:00 ET | Basilea Pharmaceutica AG
Basel, Switzerland, 10 March 2003   Basilea Pharmaceutica Ltd announced today that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for its novel...
Basilea-Logo.jpg
FDA Fast Track Designation for Basilea's Novel Broad Spectrum Antibiotic
March 10, 2003 04:00 ET | Basilea Pharmaceutica AG
Basilea Pharmaceutica Ltd announced today that it has received fast track designation from the U.S. Food and Drug Administration (FDA) for its novel broad-spectrum cephalosporin antibiotic BAL5788,...
Basilea-Logo.jpg
Amerikanische Gesundheitsbehörde bewilligt dem Schweizer Pharmaunternehmen Basilea Pharmaceutica "fast track status"
March 10, 2003 04:00 ET | Basilea Pharmaceutica AG
Der wachsende Anteil von Bakterien, die gegenüber den heute verfügbaren Antibiotika resistent sind, stellt insbesondere bei schweren Krankenhausinfektionen eine weltweite Bedrohung dar. Allein in den...
Basilea-Logo.jpg
A New Biotech Start-Up Formed Under Roche's Leadership
October 17, 2000 06:00 ET | Basilea Pharmaceutica AG
Basel, Switzerland, 17 October 2000   Basilea Pharmaceutica - a New Company in the Field of Infectious Diseases and Dermatology   Roche announced today the creation of an independent...
Basilea-Logo.jpg
A New Biotech Start-Up Formed Under Roche's Leadership
October 17, 2000 06:00 ET | Basilea Pharmaceutica AG
Basel, 17 October 2000   BASILEA Pharmaceutica - a New Company in the Field of Infectious Diseases and Dermatology   Roche announced today the creation of an independent Biotech company...